Introduction {#sec1_1}
============

Autosomal recessive congenital ichthyosis (ARCI, MIM 190195) is clinically and genetically a heterogeneous group of dermatological scaly skin disorders. It is classified into three clinical subtypes: lamellar ichthyosis (LI, MIM 242300), congenital ichthyosiform erythroderma (MIM 242100), and harlequin ichthyosis (MIM 242500) \[[@B1],[@B2]\]. Harlequin ichthyosis is fatal due to severe movement restriction and respiratory distress caused by thick hard cornified skin \[[@B1]\]. Infants affected with LI are born encased in a hyperkeratotic translucent membrane, known as collodion baby, and within 2 weeks develop large, thick, brownish lamellar scales with minimal erythema. Additionally, LI is associated with crumpled ears, alopecia, eclabium, and ectropion. On the other hand, infants affected with congenital ichthyosiform erythroderma develop fine white scales with erythroderma.

To date mutations in eight genes have been found in various subtypes of ARCI including: *ABCA12* (MIM 607800) \[[@B3]\], *NIPAL4* (MIM 609383) \[[@B4]\], *TGM1* (MIM 190195) \[[@B5]\], *ALOX12B* (MIM 603741) \[[@B6]\], *ALOXE3* (MIM 607206) \[[@B7]\], *CYP4F22* (MIM 611495) \[[@B8]\], *PNPLA1* (MIM 612121) \[[@B9]\] and *LIPN* (613924) \[[@B10]\]. Additional intervals in variants not associated with disease have also been identified \[[@B11]\]. Mutations in the transglutaminase-1 (*TGM1*) gene on 14q11.2 are the most common cause of ARCI, accounting for over 30% of the cases from diverse ethnic backgrounds \[[@B11],[@B12],[@B13],[@B14],[@B15]\]. TGM1, also known as keratinocyte transglutaminase, plays a significant role in the maturation of human epidermal cells by the formation of an isodipeptide cross-linking bond, thus assembling a highly insoluble layer known as cornified cell envelope, which in turn obviates excessive water loss and provides a protective shield against an inhospitable environment \[[@B16]\].

No previous study has been done in the Omani population with a birth prevalence of 2 LI cases per 10,000 births \[[@B17]\]. In this study, we describe clinically and genetically 9 patients from three consanguineous Omani families affected with LI.

Subjects and Methods {#sec1_2}
====================

Clinical and Laboratory Investigations {#sec2_1}
--------------------------------------

This study was approved by the institutional Ethics Committee. Subjects or their guardians gave informed consent. The patients in the three families A, B, and C (fig. [1](#F1){ref-type="fig"}) were clinically characterized by a dermatologist (A.W.). The clinical characterization of the three families is summarized in table [1](#T1){ref-type="table"}. Family A has 3 affected children. The proband, a 5-year-old male, was born with collodion membrane and mild ectropion. He was immediately started on acitretin for 5 days and his skin improved dramatically and he was discharged from the hospital within 2 weeks. According to the parents, the proband\'s siblings, a 15-year-old boy and a 13-year-old girl, were born with mild collodion membrane which improved spontaneously. The 3 children are living comfortably and require acitretin intermittently, averaging once every 2 years for 3-6 months when their condition worsens and their skin becomes more thickened and the scales become troublesome.

The 4 affected patients from family B were born with severe features of LI collodion baby, covered with a thick taut skin membrane, ectropion, eclabium, and flattening of nose and ears. These patients were initially kept on intravenous fluids, humidified incubator air, acitretin for 2 weeks and Augmentin antibiotic. After about a month and a half the skin started peeling, and patients were advised to continue with liquid paraffin treatment. Currently they have classic features of LI with brownish fish-like scales on the skin accentuating the flexures, associated with ectropion and alopecia at the temporal scalp. They are on regular emmolients and eye lubricants along with low-dose acitretin (10 mg on alternate days). It was noted that their condition worsens during the dry and windy winter months necessitating regular treatment.

The 2 affected patients from family C were known cases of LI from birth, with generalized scaling and ectropion of eyes. Patients are undergoing acitretin, and emollient treatment.

Peripheral venous blood was drawn in EDTA tubes and DNA was extracted using a commercially available kit (QIAGEN Kit), according to the manufacturer\'s instructions. The samples were initially genotyped to screen known loci linked to recessive ichthyosis on chromosomes 2q33-32 *(ABCA12)*, 14q11 *(TGM1)*, and 19p12-q12 using commercially supplied polymorphic fluorescent microsatellite markers (ABI PRISM® Linkage Mapping Sets, Linkage Mapping Set-HD5, MD10, and LD20). A total of 10 markers were used (D2S2321, D2S2361, D2S163, D14S283, D14S972, D14S275, D14S1040, D19S221, D19S226 and D19S566). DNA was amplified in 15 μl reaction volume containing 20 ng of genomic DNA, 9 μl True Allele™ PCR Premix (Part No. 403062), and 1 μl of primer mix (5 μ[M]{.smallcaps} each primer). The thermocycling condition included an initial denaturation step at 95°C for 12 min followed by a first round of 10 cycles at 94°C for 15 s, 55°C for 15 s and 72°C for 30 s. The second round of amplification was performed for 20 cycles at 89°C for 15 s, 55°C for 15 s and 72°C for 30 s, followed by final extension for 10 min at 72°C. PCR products of different labels and sizes were pooled together prior to analysis using the 310 ABI Genetic Analyzer. Once the locus was identified, the *TGM1* gene (NM_000359) was sequenced with intronic primers (available upon request) which were designed using Exon Primer Design with Primer 3 ([http://129.43.22.27/∼primer/EasyExonPrimer.html](http://www.129.43.22.27/~primer/EasyExonPrimer.html)): 15 μl reaction volume containing 20 ng of genomic DNA, 0.2 m[M]{.smallcaps} dNTP mix, 0.2 μ[M]{.smallcaps} of each primer, 1.5 m[M]{.smallcaps} MgCl~2~ and 0.025 units/μl AmpliTaq Gold. The thermocycling condition included an initial denaturation at 94°C for 12 min, followed by 40 cycles of amplification at 94°C for 30 s, 57°C (exon 5) and 60°C (exon 8) for 30 s and 72°C for 30 s and contained a final extension step at 72°C for 10 min. Sequencing reaction was performed using the Big Dye Terminator method (part No. 4336917), which was then analyzed on an ABI PRISM 3130xl Genetics Analyzer. Sequence analysis was performed using DNASTAR Lasergene, version 7 (Madison, Wisc., USA). To confirm the mutation in *TGM1*, PCR products were digested by *Nla*IV restriction enzyme for 2 h and a half at 37°C, and the digested products were analyzed using a 10% polyacrylamide gel. Following the identification of the mutations, 100 individuals from the same population were sequenced to determine the frequency of the detected mutations in the general population.

Results {#sec1_3}
=======

Homozygosity mapping for known loci linked to LI excluding 2q33-32 and 19p12-q12 showed a common haplotype in the affected families A and B for D14S972, D14S275 and D14S1040, thus suggesting the involvement of the 14q11 locus (fig. 1, family A, family B) in the pathogenesis of LI. Mutational analysis of *TGM1* detected a homozygous c.832G\>A mutation (NM_000359.2) in exon 5 in affected individuals of families A and B, while parents of both families were found to be heterozygous for the same mutation (fig. [2a](#F2){ref-type="fig"}). This substitution replaces the glycine residue at position 278 with an arginine residue, p.Gly278Arg (NP_000350). Affected members of family C had a homozygous c.1187G\>A mutation in exon 8 of *TGM1* (fig. [2b](#F2){ref-type="fig"}), resulting in a substitution of arginine for histidine at position 396: p.Arg396His. Further analysis of other family members confirmed autosomal segregations of the two mutations in the corresponding families. The presence of the c.G596A mutation was confirmed using *Nla*IV restriction mapping as shown in figure [2c](#F2){ref-type="fig"}. Neither of these two mutations were detected in 100 control samples from the same population.

Discussion {#sec1_4}
==========

In this study, the affected individuals were born with collodion membrane and maintained ectropion, and epidermal scaling through their childhood. These findings are typical features of LI subtype \[[@B2]\].

ARCI can be caused by mutations in many genes. In a large cohort of 520 ACRI families, it was found that 32% of the patients had mutations in *TGM1*, 16% in *ichthyin*, 12% in *ALOX12B*, 8% in *CYP4F22*, 5% each in *ALOXE3* and *ABCA12*, and at least 22% of these cases did not exhibit mutations in any of the known ARCI genes, implying the existence of further loci \[[@B11]\]. Additionally, mutations in *PNPLA1* and *LIPN* were recently identified in ARCI patients \[[@B9],[@B10]\]. Simple haplotype analysis using microsatellite markers linked to known loci in families of Arab origin \[[@B12],[@B18],[@B19],[@B20]\] showed a shared homozygous region between markers D14S972 and D14S275 where *TGM1* is located, demonstrating the usefulness of using homozygosity mapping for the identification of ARCI candidate genes in consanguineous families \[[@B21]\], as in this study.

Mutation analysis of *TGM1* detected p.Gly278Arg mutation in the two families A and B, indicating a common founder for the two apparently unrelated families who came from the same geographic region. Previously this mutation was found to be inherited in a compound heterozygous with p.Arg286Gln in American LI patients \[[@B22]\] and with p.Asp490Arg in a Kosovo family of Albanian origin with self-healing collodion baby \[[@B23]\]. Biochemical assay of the TGase1 p.Gly278Arg mutant found a significant loss of activity \[[@B23]\]. Molecular modeling predicted that the bulky side chain of the mutant arginine disturbed the linkage between the two β barrel domains at the interface of the catalytic core domain where the Gly278 resides \[[@B23]\]. Gly278 was found to be highly conserved among human TGase family enzymes, suggesting a conserved function \[[@B16]\].

The *TGM1* p.Arg396His mutation identified in family C was previously found to cause dramatic loss of TGase1 activity \[[@B24]\]. The Arg396 was also found in LI patients to be mutated to serine (p.Arg396Ser) \[[@B21]\] and leucine (p.Arg396Leu) \[[@B25]\]. The substitution of Arg396 for His396 at catalytic site core domain of TGase1 was shown by molecular modeling to create surface polarity without changing the structure \[[@B24]\].

To date over 130 *TGM1* mutations were found in patients from diverse ethnic backgrounds \[[@B11],[@B12],[@B13],[@B14],[@B15]\]. The detection of p.Gly278Arg and Arg396His, known mutations in our highly inbred and relatively isolated population \[[@B26]\], expands the range of *TGM1* mutations to another ethnic group and suggests an independent founder effect from that of Caucasian populations, where these two mutations were previously found.

Conclusion {#sec1_5}
==========

Two known pathogenic *TGM1* mutations were detected in three large consanguineous Omani families with LI. This study confirmed the geographic distribution of known mutations to an apparently unrelated population.

![Family pedigrees (A, B, C) affected with LI. The haplotypes of markers spanning D14S972 to D14S1040 show the homozygous region shared by the affected subjects in families A and B. Pedigree symbols: ◻ = male, ⚪ = female; a diagonal line designates deceased, and filled boxes or circles designate affected.](mpp-0022-0438-g01){#F1}

![DNA sequences of *TGM1* showing c.832G\>A mutation in exon 5 detected in families A and B (**a**), c.1187G\>A mutation in exon 8 detected in family C (**b**) and ethidium bromide-stained 10% polyacrylamide gel electrophoresis of *Nla*IV restriction digestion at the c.832G\>A mutation site where G-to-A substitution eliminated *Nla*IV site in the 317-bp fragment (**c**). A = Affected; C = carrier; N = normal.](mpp-0022-0438-g02){#F2}

###### 

Clinical characterization of affected families

  Feature                                        Family                                                                                                 
  ---------------------------------------------- ---------------------------- ------------------------------------------------------------------------- --------------------------------------
  Patients, n                                    3                            4                                                                         2
                                                                                                                                                        
  Collodion membrane at birth                    \+                           \+                                                                        \+
                                                                                                                                                        
  Ectropion at birth                             \+                           \+                                                                        \+
                                                                                                                                                        
  Eclabium at birth                              --                           \+                                                                        --
                                                                                                                                                        
  Flattening of nose and ears at birth           --                           \+                                                                        --
                                                                                                                                                        
  Childhood generalized scaling                  mild                         fish-like                                                                 mild
                                                                                                                                                        
  Ectropion and alopecia at the temporal scalp   --                           \+                                                                        --
                                                                                                                                                        
  Current treatment                              acitretin (intermittently)   emollients and eye lubricants along with low-dose acitretin (regularly)   acitretin and emollient (frequently)
                                                                                                                                                        
  Severity of the condition                      mild                         severe                                                                    mild

The sign + denotes the presence and the sign -- denotes the absence.
